These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, RBC Capital Markets maintained their Sector Perform rating on CME Group shares (NASDAQ:CME), with a steady price target of $269.00. The firm’s analysis highlighted the company’s ability to capture growth during market fluctuations, noting that elevated volatility is likely to contribute to strong volume growth in the second quarter of 2025. RBC Capital analysts pointed out that the increased retail adoption of micro-futures and international expansion are expected to further drive solid growth for CME Group. Currently trading at $264.71, near its 52-week high of $273.42, CME has demonstrated strong momentum with a 28.7% return over the past year. InvestingPro analysis shows that 8 analysts have recently revised their earnings estimates upward for the upcoming period, suggesting growing confidence in the company’s prospects.
The analysts also observed that the Market and Data Information segment of CME Group is benefiting from a rise in subscriber numbers and pricing advantages, with a forecasted increase of 3.5% in fiscal year 2025. The implementation of a non-cash collateral surcharge, which started on April 1, is anticipated to have a positive impact as well. The company’s strong financial position is evident in its impressive 11.7% revenue growth over the last twelve months, while maintaining a consistent dividend track record spanning 23 years, with a current attractive yield of 4.13%.
RBC Capital’s commentary included that CME Group’s stock has experienced a rally and significant outperformance compared to the broader market year-to-date, thanks to the tailwinds from increased market volatility. The firm suggests that CME Group shares should continue to act as a solid hedge in portfolios amidst macroeconomic uncertainty.
CME Group’s performance is closely tied to market volatility, as it often leads to higher trading volumes and, consequently, increased revenue for the company. With the continuation of such market conditions, CME Group is positioned to potentially sustain its growth trajectory as indicated by RBC Capital’s analysis.
In other recent news, CME Group reported its first-quarter 2025 earnings, surpassing analyst expectations with an adjusted EPS of $2.80, compared to the forecasted $2.68. The company also achieved a record quarterly revenue of $1.64 billion, beating the anticipated $1.59 billion. Despite these strong financial results, CME Group’s stock experienced a decline, which analysts attribute to broader market trends rather than company performance. Barclays (LON:BARC) adjusted its price target for CME Group shares to $283 from $279, maintaining an Equalweight rating, following the earnings report. Raymond (NSE:RYMD) James also raised its price target to $297 from $287, continuing to rate the stock as Outperform, citing confidence in the company’s strategic position amidst volatile economic conditions. CME Group’s recent performance has been bolstered by record trading volumes across multiple products, driven by increased market volatility. Additionally, the company is expanding its international and product offerings, with a focus on technology investments, which are expected to rise along with professional fees and marketing expenses. These developments underscore CME Group’s strategic focus and resilience in navigating the current economic landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.